查詢結果分析
來源資料
相關文獻
- New One-Week, Low-Dose Triple Therapy for the Treatment of Duodenal Ulcer with Helicobacter Pylori Infection
- The Role of Gastric Acid and Helicobacter Pylori in the Natural Course of Duodenal Ulcer
- 含Lansoprazole雙重或三合療法治療十二指腸潰瘍合併幽門螺旋桿菌感染之效果比較
- The Hemodynamic Changes of Gastroduodenal Regional Blood Flow after Helicobacter Pylorieradication in Patients with Duodenal Ulcer Scar
- The iceA1 and iceA2 Genotypes of Helicobactor pylori are Associated with the Duodenal Ulcer
- A One-Week Low-Dose New Triple Therapy for Treatment of Duodenal Ulcer with Helicobacter Pylori Infection
- A Comparison of the Efficacy between Denol-Based and Zantac-Based Triple Therapy for Recurrent Duodenal Ulcer Accompanied with Helicobacter Pylori Infection
- Eradication of Helicobacter Pylori with Omeprazole-Amoxicillin Combination Therapy Versus Famotidine--A Randomized, Controlled Study
- Helicobacter Pylori Infection and Duodenal Ulcer in Children and Adolescents
- 幽門螺旋桿菌與胃腸疾病
頁籤選單縮合
題 名 | The Role of Gastric Acid and Helicobacter Pylori in the Natural Course of Duodenal Ulcer=胃酸和幽門螺旋桿菌在十二指腸潰瘍自然史扮演之角色 |
---|---|
作 者 | 楊智欽; 林伯儒; 王錦堂; 陳惟浩; 林肇堂; 王德宏; | 書刊名 | 微免與感染雜誌 |
卷 期 | 32:3 1999.09[民88.09] |
頁 次 | 頁155-162 |
分類號 | 415.5 |
關鍵詞 | 幽門螺旋桿菌; 十二指腸潰瘍; Helicobacter pylori; Duodenal ulcer; Recurrence; Roxatidine; Mylanta; |
語 文 | 英文(English) |
中文摘要 | 83位幽門螺旋桿菌陽性之十二指腸潰瘍患者隨機分為四組接受為期8週之治療,A組21例,給予一般H2受體拮抗劑roxatidine 75mg,每晚一次:B組21例,除了同A組外,另於第3週合併使用amoxicillin及metronidazole各250 mg,每天四次,共7天:C組20例,給予一般胃酸中和劑Mylanta 20毫升,每天四次:D組21例,除了同C組外,另於第3週合併用上述抗生素,共7天。對潰瘍己癒合之病人繼續追蹤1年。病人於治療前、治療8週結束、追蹤期為6個月及12個月後,均接受胃鏡檢查,觀察潰瘍的狀況,並於胃之前庭部及體部拿取組織切片做細菌培養、病理及快速尿素�t檢驗,來判斷幽門螺旋桿菌之存在與否。結果: 潰瘍癒合率在A、B、C、D四組分別為95%,100%,61%及86%,其中A組顯著優於C組。對幽門螺旋桿菌的清除率則四組分別為0%,81%,0%,62%。其中 B 組和 D 組之差異未達顯著水準,於12個月後,潰瘍之累積復發率為75%,15%,80%及22%。使用抗生素之兩組顯著優於未使用組。結論為強力的胃酸抑制對潰瘍癒合即有良好效果。而幽門螺旋桿菌的清除在僅有輕度或暫時胃酸抑制的情況下有助於加速潰瘍的癒合。細菌清除後可使潰瘍之復發率明顯降低,顯示幽門螺旋桿菌在十二指腸潰瘍的自然史中扮演重要的角色。 |
英文摘要 | This study was conducted using roxatidine acetate or Mylanta combined with metronidazole and amoxicillin to evaluate the role of acid and Helicobacter pylori in the natural course of the duodenal ulcer. Eighty-three patients with H. pylori positive duodenal ulcers were randomly allocated into one of four treatment groups. Group A: roxatidine 75 mg hs for 8 weeks; Group B: the same as group A + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week; Group C: Mylanta (combined hydroxide of magnesium and aluminum) 20ml qid for 8 weeks; Group D: the same as group C + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week. Repeated endoscopies were performed on the 8th week post the initial treatment and the sixth and 12th month post the termination of treatment, or, at the earliest recurrence of symptoms. Eradication of H. pylori was considered to be successful if the culture, histology and CLO test all showed negative. The ulcer healing rates of Groups A, B, C and D were 95%, 100%, 61% and 86%, respectively, with a significant difference between A and C. The eradication rates of groups B and D were 81% and 62%, respectively, without any significant difference. The 12 months cumulative ulcer recurrence rates were 72%, 15%, 80% and 22%, respectively, with a significant difference between each paired groups with and with-out antibiotics. In conclusions, roxatidine is effective in the healing of duodenal ulcer. One-week roxatidine-based triple therapy is powerful in the eradication of H. pylori. Potent acid suppression is sufficient to heal the duodenal ulcer. Eradication of H. pylori can potentiate ulcer healing under insufficient acid suppression. A causal role for H. pylori in recurrent duodenal ulcer is strongly supported by a much lower recurrence of ulcer in H. pylori free patients. |
本系統中英文摘要資訊取自各篇刊載內容。